PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1514007
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1514007
Endometriosis Drugs
Global Endometriosis Drugs Market to Reach US$3.6 Billion by 2030
The global market for Endometriosis Drugs estimated at US$3.0 Billion in the year 2023, is expected to reach US$3.6 Billion by 2030, growing at a CAGR of 3.0% over the analysis period 2023-2030. Hormone Therapy, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$2.2 Billion by the end of the analysis period. Growth in the Analgesics segment is estimated at 2.6% CAGR over the analysis period.
The U.S. Market is Estimated at US$794.7 Million While China is Forecast to Grow at 2.9% CAGR
The Endometriosis Drugs market in the U.S. is estimated at US$794.7 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$580.1 Million by the year 2030 trailing a CAGR of 2.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 2.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.0% CAGR.
Endometriosis Drugs - Key Trends and Drivers
Endometriosis is a chronic gynecological condition characterized by the growth of endometrial-like tissue outside the uterus, causing severe pain, irregular bleeding, and infertility. Managing this condition often requires a multifaceted approach, including surgical intervention and pharmacological treatment. Endometriosis drugs primarily aim to alleviate pain, reduce inflammation, and manage the hormonal imbalances associated with the disease. The most commonly prescribed medications include nonsteroidal anti-inflammatory drugs (NSAIDs) for pain relief, hormonal contraceptives to regulate menstrual cycles, and gonadotropin-releasing hormone (GnRH) agonists and antagonists to lower estrogen levels and shrink endometrial tissue. Other treatments involve progestins, which mimic the hormone progesterone to suppress endometrial growth, and aromatase inhibitors, which reduce estrogen production. These therapeutic strategies are critical in providing symptom relief and improving the quality of life for women suffering from endometriosis.
Several trends are shaping the landscape of endometriosis drug development and treatment. One significant trend is the growing focus on personalized medicine, where treatments are tailored to the individual’s specific genetic, hormonal, and symptomatic profile. This approach is gaining traction as researchers uncover more about the underlying mechanisms of endometriosis, leading to the development of targeted therapies that promise greater efficacy and fewer side effects. Additionally, there is an increasing interest in non-hormonal treatments due to the side effects and contraindications associated with long-term hormonal therapy. Innovations in this area include drugs that target the inflammatory pathways and pain receptors specific to endometriosis. Furthermore, advancements in diagnostic tools, such as molecular imaging and biomarker identification, are improving early detection and monitoring of the disease, allowing for more timely and effective intervention.
The growth in the endometriosis drugs market is driven by several factors. Technological advancements in drug discovery and development are enabling the creation of novel therapies with improved safety and efficacy profiles. The increasing prevalence of endometriosis, coupled with heightened awareness and better diagnosis rates, is expanding the patient population requiring treatment. Additionally, the shift towards personalized and precision medicine is fostering the development of customized treatment plans that cater to the unique needs of each patient, enhancing therapeutic outcomes. The demand for non-hormonal treatment options is also propelling market growth, as these alternatives offer solutions for patients who cannot tolerate hormonal therapies. Furthermore, substantial investments in research and development by pharmaceutical companies, along with supportive government initiatives and funding for women's health, are accelerating the introduction of new and effective endometriosis treatments. These combined factors are driving robust growth in the endometriosis drugs market, meeting the urgent needs of affected women worldwide.
Select Competitors (Total 38 Featured) -
- AbbVie Inc.
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bayer AG
- Debiopharm Group
- Evotec AG
- Kissei Pharmaceutical Co. Ltd.
- Neurocrine Biosciences Inc.
- ObsEva SA
- Pfizer Inc.
- Repros Therapeutics Inc.
- Takeda Pharmaceutical Company Limited
- ValiRx plc
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- Global Economic Update
- Endometriosis Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Increasing Focus on Personalized Medicine Propels Growth in Endometriosis Treatments
- Innovations in Non-Hormonal Therapies Expand Addressable Market Opportunity
- Advances in Diagnostic Tools Strengthen Business Case for Early Detection and Treatment
- Rising Prevalence of Endometriosis Drives Demand for Effective Drugs
- Advancements in Drug Discovery Accelerate Development of Novel Therapies
- Improved Awareness and Diagnosis Rates Spur Growth in Endometriosis Drug Market
- Demand for Non-Hormonal Treatment Options Generates Opportunities for New Therapies
- Development of Targeted Therapies Enhance Treatment Efficacy and Safety
- Impact of Personalized and Precision Medicine on Treatment Plans and Patient Outcomes
- Consumer Demand for Effective and Safer Treatment Options Spurs Market Demand
- Advancements in Molecular Imaging and Biomarker Identification Enhance Disease Monitoring
- Shift towards Tailored Treatment Plans Throws the Spotlight on Patient-Centric Care
- Challenges in Long-Term Hormonal Therapy Drive Interest in Alternative Treatments
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Endometriosis Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Endometriosis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 3: World Historic Review for Endometriosis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 4: World 16-Year Perspective for Endometriosis Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Hormone therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 6: World Historic Review for Hormone therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 7: World 16-Year Perspective for Hormone therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 9: World Historic Review for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 10: World 16-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
- TABLE 11: USA Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 12: USA Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 13: USA 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2024 & 2030
- CANADA
- TABLE 14: Canada Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 15: Canada Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 16: Canada 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2024 & 2030
- JAPAN
- Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
- TABLE 17: Japan Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 18: Japan Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 19: Japan 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2024 & 2030
- CHINA
- Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
- TABLE 20: China Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 21: China Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 22: China 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2024 & 2030
- EUROPE
- Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
- TABLE 23: Europe Recent Past, Current & Future Analysis for Endometriosis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 24: Europe Historic Review for Endometriosis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 25: Europe 16-Year Perspective for Endometriosis Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
- TABLE 26: Europe Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 27: Europe Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 28: Europe 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2024 & 2030
- FRANCE
- Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
- TABLE 29: France Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 30: France Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 31: France 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2024 & 2030
- GERMANY
- Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
- TABLE 32: Germany Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 33: Germany Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 34: Germany 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2024 & 2030
- ITALY
- TABLE 35: Italy Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 36: Italy Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 37: Italy 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2024 & 2030
- UNITED KINGDOM
- Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
- TABLE 38: UK Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 39: UK Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 40: UK 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2024 & 2030
- REST OF EUROPE
- TABLE 41: Rest of Europe Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 42: Rest of Europe Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 43: Rest of Europe 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2024 & 2030
- ASIA-PACIFIC
- Endometriosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
- TABLE 44: Asia-Pacific Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 45: Asia-Pacific Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 46: Asia-Pacific 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2024 & 2030
- REST OF WORLD
- TABLE 47: Rest of World Recent Past, Current & Future Analysis for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 48: Rest of World Historic Review for Endometriosis Drugs by Product Type - Hormone therapy and Analgesics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 49: Rest of World 16-Year Perspective for Endometriosis Drugs by Product Type - Percentage Breakdown of Value Sales for Hormone therapy and Analgesics for the Years 2014, 2024 & 2030
IV. COMPETITION
